Journal Finder

Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our http://www.elsevier.com/wps/find/authorsview.authors/authorservicesauthor services.

Please see our http://www.elsevier.com/wps/find/journaldescription.cws_home/725535/authorinstructionsGuide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Clinical Cancer Drugs publishes original research and (as well as) expert reviews, and thematic issues in all core areas of translational and clinical cancer drug research.

Clinical Cancer Research, is a journal of the American Association for Cancer Research whose focus is to publish innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. The journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease. Clinical Cancer Research will publish articles that provide the reader with knowledge and information to impact the natural history of malignant disease by providing better care for patients with cancer.

Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Clinical & Experimental Metastasis is an international, multidisciplinary journal devoted to the rapid publication of fundamental advances in basic and applied metastasis research.The coverage encompasses all aspects of metastasis research, whether laboratory-based, experimental or clinical and therapeutic. It includes such areas as molecular biology, pharmacology, tumour biology, and clinical cancer treatment (with all its subdivisions of surgery, chemotherapy and radio-therapy as well as pathology and epidemiology) insofar as these disciplines are concerned with the journal's core subject of metastasis formation, prevention and treatment.Clinical & Experimental Metastasis is the official journal of the Metastasis Research Society.

Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of biomarkers for cancer diagnosis, prognosis or prediction of treatment response, identification of new targets for cancer therapy, as well as development of new technologies for research and treatment of cancer are the major themes covered by both the educational series and research articles. A broad spectrum of subjects, including the molecular and cellular bases of di

The primary objective of "Critical ReviewsTM in Oncogenesis" is the advancement and dissemination of scientific and clinical knowledge relating to the molecular basis of Oncogenesis for both its originality and scientific merit. CRO is dedicated to publishing timely critical reviews on topics of current interests with emphasis in basic, molecular and translational applications in the field of Oncogenesis. Further emphasis will also be placed on the role Oncogenesis in the development of cancer and malignancies as well as the role of cancer stem cells and their oncogenic potential. Reviews will also consider the role of oncogenes as diagnostics and therapeutic targets. This journal will publish special thematic issues on selected topics such as described above and employing many multidisciplinary approaches. Articles are by invitation only.In contrast to reviews in several other publications, CRO will be focused on its specific and unique thematic approach for each issue that is contributed by various experts in and, often, an invited Guest Editor will be appointed for a particular issue. This multidisciplinary approach for a specific topic in Oncogenesis will distinguish CRO from many other journals whereby individual reviews are published. We believe that the new CRO objective will lead to a wide readership and will be used as an essential reference for research scientists, clinicians, students, and health professionals. The new Aims and Scope of CRO are designed to interest a wide readership and make it a reference standard in Oncogenesis.

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

Current Cancer Therapy Reviews publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.

Current Opinion in Oncology Online provides a powerful, broad-based perspective on the most important advances in the field from throughout the world literature. Reader-friendly, the journal features renowned guest editors focusing exclusively on two topics each issue. Bimonthly, every issue of Current Opinion in Oncology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as endocrine tumors; melanoma and other skin neoplasms; the genitourinary system; supportive care; cancer in AIDS; and the breast--some 18 or more items in all of major relevance. All reviews are supplemented with an indispensable section, 'References and Recommended Reading'. At the back of each volume is 'Current World Literature', an exceptionally thorough bibliography culled from the top 100 journals in the field.Website: www.co-oncology.com.

Each bimonthly issue of Current Problems in Cancer presents a single-topic, in-depth discussion, usually focused on the integrated management of a particular type of cancer or on a problem faced in a wide variety of malignancies. Issues may explore a particular category of drugs, an emerging interventional technique, or rehabilitation/reconstruction. Extensive bibliographies allow readers to easily locate additional information on related topics. Current Problems in Cancer serves the wide spectrum of physicians who treat patients with neoplastic disease.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.If you require any further information or help, please visit our support pages: http://support.elsevier.com

Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT).Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, physicians, and regulatory experts involved in cell processing and therapy.The journal's scope includes research in:Stem cell processing and transplantationCell-based therapies of malignant and non-malignant blood diseasesCancerStem cell plasticityAutoimmune diseasesImmunotherapyCongenital disordersNovel molecular therapiesGene therapyMicrovesicle biology and therapeutic application

Differentiation is a multidisciplinary journal dealing with topics relating to cell differentiation, development, cellular structure and function, and cancer. Differentiation of eukaryotes at the molecular level and the use of transgenic and targeted mutagenesis approaches to problems of differentiation are of particular interest to the journal.The journal will publish full-length articles containing original work in any of these areas. We will also publish reviews and commentaries on topics of current interest. The principal subject areas the journal covers are: • embryonic patterning and organogenesis• mechanisms of cell lineage commitment• tissue homeostasis• establishment of cellular polarity• stem cell differentiation• cell reprogramming mechanisms• stability of the differentiated state• cell and tissue interactions in vivo and in vitro• signal transduction pathways in development and differentiation• carcinogenesis and cancer• mechanisms involved in cell growth and division especially relating to cancer• differentiation in regeneration and ageing

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance.It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Endocrine-Related Cancer is the established global journal for basic, translational and clinical research on hormones and cancer. Endocrine-related cancers typically include cancers of the breast, prostate, pituitary, testes, ovary and neuroendocrine system as well as hormone-dependent cancers elsewhere.

Epigenetics is a multidisciplinary peer-reviewed journal that publishes original research and review articles covering the latest findings about epigenetic mechanisms and their role in diverse biological processes.Our goal is to establish Epigenetics as the lead journal in the field by providing a forum where epigenetic approaches to a variety of medical and biological issues can be discussed and the common basic principles of epigenetics spanning different systems can be revealed and shared.The field of epigenetics studies the changes in gene expression that are caused by mechanisms other than the modification of the DNA sequence. Epigenetics covers many different levels of biological control and relates to diverse biological systems, diseases and disciplines. Although in recent years cancer has been the main focus of epigenetic studies, recent data suggests that epigenetics also plays critical roles in psychology and psychopathology. It is being realized that normal behaviors, such as maternal care, and pathologies, such as Schizophrenia and Alzheimer disease, might have an epigenetic basis. It is also becoming clear that nutrition and life experiences have consequences that are mediated by epigenetic mechanisms. The increasing awareness of the potential role of epigenetic deregulation in disease has spawned the development of diagnostic and therapeutic approaches using epigenetics. Although the questions asked are diverse, the unifying hypothesis is that epigenetics is involved. The journal provides a platform for developing unifying methodologies, hypotheses, experimental approaches and diagnostic agents and serves as a meeting place for researchers working in different systems such as general biology, plant biology, cancer biology, cancer therapeutics, epigenetic pharmacology, neurobiology and psychiatry, who are unraveling the epigenetic facets of their specific fields of interest.

Epigenomics promises to elucidate the inner workings of the genome. The power of this new discipline lies in its promise to provide us with novel insights into the inner workings of our genomes through its potential to detect quantitative changes, multiple modifications and the regulatory sequences outside that of our gene sequences. The advent of numerous epigenomics strategies has emerged to detect large numbers of DNA methylation variations and chromatin modifications – two mechanisms that are at the core of epigenomic research. Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time-constrained community.